玻璃体腔注射雷珠单抗联合口服二十二碳六烯酸与抗氧化剂补充治疗糖尿病性黄斑水肿:两年随机单盲对照试验结果
该随机单盲对照试验纳入62例糖尿病性黄斑水肿患者,比较玻璃体腔注射雷珠单抗单用与联合口服二十二碳六烯酸(DHA,1,050 mg/天)及抗氧化剂补充治疗2年的效果。结果显示,联合DHA组在24个月时黄斑中心亚区厚度下降幅度显著优于单用组(差值95%CI 7.20-97.656,P=0.024),但最佳矫正视力(ETDRS字母)改善未达统计学显著(95%CI 5.4-11.2,P<0.66)。结论认为联合DHA补充可降低黄斑中心亚区厚度,解剖学改善伴随视力改善趋势。
要点
- 联合DHA组24个月黄斑中心亚区厚度下降显著优于雷珠单抗单用组(P=0.024)。
- 最佳矫正视力改善未达统计学显著(95%CI 5.4-11.2,P<0.66)。
- 考虑较差眼与较好眼时,联合DHA组视力增益>5和>10字母显著更高,但其他差异未发现。
核心结论
- 玻璃体腔注射雷珠单抗联合DHA补充治疗2年随访可降低糖尿病性黄斑水肿患者的黄斑中心亚区厚度,解剖学改善伴随视力改善趋势。
研究设计与样本
- 随机单盲对照研究,纳入62例糖尿病性黄斑水肿患者,33例(42眼)接受雷珠单抗单用,29例(34眼)接受雷珠单抗联合DHA(1,050 mg/天)。
- 雷珠单抗(0.5 mg)前4个月每月注射,之后按需治疗。
主要发现
- 24个月时,黄斑中心亚区厚度下降组间差异显著,支持DHA补充组(差值95%CI 7.20-97.656,P=0.024)。
- 最佳矫正视力(ETDRS字母)改善未达统计学显著(95%CI 5.4-11.2,P<0.66)。
- 24个月时,考虑较差眼与较好眼时,DHA补充组视力增益>5和>10字母显著高于对照组,但12个月和24个月其他差异未发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the 2-year effectiveness of intravitreal ranibizumab combined with a dietary supplement rich in docosahexaenoic acid (DHA) plus antioxidants in 62 patients with diabetic macular edema. METHODS: In a randomized single-blind controlled study, 33 subjects (42 eyes) received intravitreal ranibizumab alone and 29 (34 eyes) combined with DHA (1,050 mg/day). Monthly ranibizumab (0.5 mg) was given for the first 4 months followed by on as-needed treatment. RESULTS: At 24 months, the difference between groups in the decrease of central subfield macular thickness was significant in favor of the DHA supplementation group (95% confidence interval of the difference 7.20-97.656; P = 0.024), although improvement in best-corrected visual acuity measured in the Early Treatment Diabetic Retinopathy Study letters did not reach statistical significance (95% confidence interval 5.4-11.2, P < 0.66). At 24 months, gains of >5 and >10 letters were significantly higher in the DHA supplementation group as compared with controls when the worse and better seeing eyes were considered but other differences at 12 months and 24 months were not found. CONCLUSION: Intravitreal ranibizumab combined with DHA supplementation reduced central subfield macular thickness after 2 years of follow-up as compared with ranibizumab alone in patients with diabetic macular edema. This anatomical improvement was accompanied by a trend for an amelioration of vision.
引用
- Lafuente M, Ortín L, Argente M, et al. COMBINED INTRAVITREAL RANIBIZUMAB AND ORAL SUPPLEMENTATION WITH DOCOSAHEXAENOIC ACID AND ANTIOXIDANTS FOR DIABETIC MACULAR EDEMA: Two-Year Randomized Single-Blind Controlled Trial Results. Retina. 2017. PMID: 27787443. doi:10.1097/IAE.0000000000001363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。